United Therapeutics | UTHR - Selling And Administration Expenses

Stock Price
474.47
Daily Change
1.05 0.22%
Monthly
0.23%
Yearly
32.46%
Q1 Forecast
458.74

United Therapeutics reported $152M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Amarin USD 17.94M 17.86M Sep/2025
Ardelyx USD 83.61M 378K Sep/2025
Baxter International USD 761M 53M Dec/2025
Bayer EUR 3.4B 140M Sep/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
J&J USD 6.75B 831M Dec/2025
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
Moderna USD 308M 40M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025